Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade.

Thiethylperazine (Torecan) is a piperazine phenothiazine employed to relieve vertigo. Its use may be associated with extrapyramidal side effects (dystonia, akathisia, tardive dyskinesia) (Sulkava, 1984), but parkinsonism has rarely been described. We describe a woman who, 1 month after the onset of thiethylperazine treatment, developed parkinsonism that disappeared 2 months after withdrawal of the drug. However, cerebral single-photon emission computed tomography (SPECT) with the dopamine (DA) D2 receptors ligand 123I-iodobenzamide (123I-IBZM) revealed a persistent reduced DA D2 receptors activity (by 45%) in the basal ganglia (BG), which may be clinically not effective.

Citation

C Briani, A Cagnin, F Chierichetti, M Tiberio, L Battistin, G Pizzolato. Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade. European journal of neurology. 2004 Oct;11(10):709-10

Mesh Tags

Substances

PMID: 15469457

search → result